Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Recruiting
Neurocrine Biosciences
Phase 3
2020-07-23
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont
versus placebo administered for 24 weeks in approximately 165 adult subjects with classic CAH
due to 21-hydroxylase deficiency. The study consists of a 6 month randomized, double blind,
placebo-controlled period, followed by 1 year of treatment with crinecerfont. Duration of
participation is approximately 20 months.
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
Recruiting
Neurocrine Biosciences
Phase 3
2021-06-24
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont
versus placebo administered for 28 weeks in approximately 81 pediatric patients with classic
congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of
a 28-week double blind, placebo-controlled period, followed by 24 weeks of treatment with
crinecerfont. Duration of participation is approximately 14 months.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
